News from SGC

Posted on Thursday 12th of January 2017

Scientists from the Structural Genomics Consortium (SGC) and Oxford University report the first potent and selective chemical probe for the bromodomain of PCAF in an article published in Angewandte Chemie International Edition

Posted on Thursday 12th of January 2017

The study of proteins is a key aspect of the drug design process. 

Posted on Monday 9th of January 2017

SGC's director, Aled Edwards, pens an op-ed in The Globe and Mail on stimulating innovation in Canada with open science. Full article here

Posted on Monday 9th of January 2017

In collaboration with the SGC and the Genetic Alliance, the UNC Catalyst at the University of North Carolina will give researchers the tools and knowledge to tackle rare and orphaned diseases. The initiative was launched with a $2 million grant from the Eshelman Institute for Innovation. For the full news release, please read here.

 

 

Posted on Thursday 5th of January 2017

We review this month the role(s) of bromodomains (BRDs), evolutionary conserved protein–protein interaction modules that are found in a wide range of proteins with diverse catalytic and scaffolding functions, present in most tissues. BRDs selectively recognize and bind to acetylated lysine residues, particularly acetylated histones and thereby play important roles in regulating gene expression.

Posted on Monday 19th of December 2016

http://www.nature.com/nsmb/journal/vaop/ncurrent/full/nsmb.3343.html

Oxford, UK, December 19, 2016, Scientists from the Structural Genomics Consortium (SGC) and Oxford University report a three-dimensional view of the Polycystin-2 (PC2), a protein that causes autosomal dominant polycystic kidney disease (ADPKD) when mutated, in an article published today in Nature Structural and Molecular Biology.

Posted on Thursday 3rd of November 2016

Bromodomains (BRDs) have emerged as compelling targets for cancer therapy, however the complex multidomain/subunit architecture of BRD-protein complexes complicates predictions of consequences of their pharmacological targeting

Posted on Friday 7th of October 2016

Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award.

Posted on Monday 12th of September 2016

Target-enabling packages provide a crucial link between human genetics and disease biology to accelerate drug discovery in cancer and malaria

Posted on Friday 5th of August 2016

A groundbreaking partnership between the Alzheimer’s Research UK Drug Discovery Alliance (DDA) and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and enabling new clinical trials, quickly.

Pages

Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03